Your session is about to expire
← Back to Search
Microfluidics Device
A Sibling Oocyte Study- Comparison of ZyMotTM Microfluidics Device to Density Gradient for Sperm Selection During ICSI
N/A
Waitlist Available
Led By Rani Fritz, DO, PhD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up culture day 5 or 6
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing if a new method to pick the healthiest sperm can improve embryo quality for couples undergoing fertility treatments. The method uses a special device that only lets the strongest sperm through a tiny filter.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ culture day 5 or 6
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~culture day 5 or 6
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Percentage of Good Quality Blastocyst Formation
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: ZyMot SeparationExperimental Treatment1 Intervention
Treatment
Group II: Density Gradient CentrifugationActive Control1 Intervention
Control
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ZyMot Multi Sperm Separation Device (850 ul)
2021
N/A
~110
Find a Location
Who is running the clinical trial?
NYU Langone HealthLead Sponsor
1,415 Previous Clinical Trials
856,095 Total Patients Enrolled
Rani Fritz, DO, PhDPrincipal InvestigatorNYU Langone Health